Robert A Weinberg

List of Publications by Year
in descending order

133 papers	173,174 citations	2675 95 h-index	11308 136 g-index
139 all docs	139 docs citations	139 times ranked	138659 citing authors

#	Article	IF	Citations
1	Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nature Cell Biology, 2022, 24, 554-564.	10.3	53
2	Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. Cancer Discovery, 2021, 11, 384-407.	9.4	64
3	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. Cancer Discovery, 2021, 11, 362-383.	9.4	50
4	Direct and Indirect Regulators of Epithelialâ€"Mesenchymal Transitionâ€"Mediated Immunosuppression in Breast Carcinomas. Cancer Discovery, 2021, 11, 1286-1305.	9.4	76
5	Linking EMT programmes to normal and neoplastic epithelial stem cells. Nature Reviews Cancer, 2021, 21, 325-338.	28.4	273
6	Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. Nature Communications, 2021, 12, 5680.	12.8	18
7	Leveraging immunochemotherapy for treating pancreatic cancer. Cell Research, 2021, 31, 1228-1229.	12.0	2
8	An EMTâ€"primary ciliumâ€"GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis. Science Advances, 2021, 7, eabf6063.	10.3	14
9	David M. Livingston (1941â€"2021). Cancer Cell, 2021, 39, 1560-1561.	16.8	0
10	Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature, 2020, 585, 603-608.	27.8	420
11	Emerging Mechanisms by which EMT Programs Control Stemness. Trends in Cancer, 2020, 6, 775-780.	7.4	133
12	Guidelines and definitions for research on epithelialâ€"mesenchymal transition. Nature Reviews Molecular Cell Biology, 2020, 21, 341-352.	37.0	1,195
13	Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16971-16980.	7.1	92
14	How TP53 (almost) became an oncogene. Journal of Molecular Cell Biology, 2019, 11, 531-533.	3.3	1
15	Syndecan-Mediated Ligation of ECM Proteins Triggers Proliferative Arrest of Disseminated Tumor Cells. Cancer Research, 2019, 79, 5944-5957.	0.9	6
16	EMT and Cancer: More Than Meets the Eye. Developmental Cell, 2019, 49, 313-316.	7.0	218
17	Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7353-7362.	7.1	366
18	New insights into the mechanisms of epithelialâ€"mesenchymal transition and implications for cancer. Nature Reviews Molecular Cell Biology, 2019, 20, 69-84.	37.0	2,319

#	Article	IF	Citations
19	Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 2018, 24, 541-550.	30.7	3,421
20	The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Science Translational Medicine, 2018, 10, .	12.4	301
21	Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Frontiers of Medicine, 2018, 12, 361-373.	3.4	467
22	Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling. Cell Reports, 2018, 24, 962-972.	6.4	51
23	IL-1Î² inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nature Cell Biology, 2018, 20, 1084-1097.	10.3	122
24	An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. ELife, 2018, 7, .	6.0	91
25	Emerging Biological Principles of Metastasis. Cell, 2017, 168, 670-691.	28.9	2,208
26	Integrin-Î²4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2337-E2346.	7.1	273
27	EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature Reviews Clinical Oncology, 2017, 14, 611-629.	27.6	1,865
28	Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. Cancer Research, 2017, 77, 3982-3989.	0.9	294
29	LACTB is a tumour suppressor that modulates lipid metabolism and cell state. Nature, 2017, 543, 681-686.	27.8	131
30	EMT programs promote basal mammary stem cell and tumor-initiating cell stemness by inducing primary ciliogenesis and Hedgehog signaling. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10532-E10539.	7.1	104
31	Upholding a role for EMT in breast cancer metastasis. Nature, 2017, 547, E1-E3.	27.8	266
32	Upholding a role for EMT in pancreatic cancer metastasis. Nature, 2017, 547, E7-E8.	27.8	203
33	Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. Journal of Experimental Medicine, 2017, 214, 2243-2255.	8.5	187
34	The SUMO guards for SNAIL. Oncotarget, 2017, 8, 97701-97702.	1.8	5
35	Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-Based Therapy. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 11-19.	1.1	51
36	Neutrophils Suppress Intraluminal NK Cellâ€“Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. Cancer Discovery, 2016, 6, 630-649.	9.4	369

#	Article	IF	Citations
37	Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency. Cancer Research, 2016, 76, 6778-6784.	0.9	125
38	EMT, cell plasticity and metastasis. Cancer and Metastasis Reviews, 2016, 35, 645-654.	5.9	672
39	Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science, 2016, 351, aad3680.	12.6	271
40	How Does Multistep Tumorigenesis Really Proceed?. Cancer Discovery, 2015, 5, 22-24.	9.4	134
41	Asymmetric apportioning of aged mitochondria between daughter cells is required for stemness. Science, 2015, 348, 340-343.	12.6	463
42	Epithelialâ€"Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends in Cell Biology, 2015, 25, 675-686.	7.9	832
43	Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature, 2015, 525, 256-260.	27.8	604
44	The Epithelial-Mesenchymal Transition Factor SNAIL Paradoxically Enhances Reprogramming. Stem Cell Reports, 2014, 3, 691-698.	4.8	75
45	Coming Full Circleâ€"From Endless Complexity to Simplicity and Back Again. Cell, 2014, 157, 267-271.	28.9	225
46	The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nature Cell Biology, 2014, 16, 717-727.	10.3	732
47	A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nature Cell Biology, 2014, 16, 1105-1117.	10.3	380
48	Tackling the cancer stem cells â€" what challenges do they pose?. Nature Reviews Drug Discovery, 2014, 13, 497-512.	46.4	831
49	Dihydropyrimidine Accumulation Is Required for the Epithelial-Mesenchymal Transition. Cell, 2014, 158, 1094-1109.	28.9	186
50	Protein Kinase C Î± Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells. Cancer Cell, 2013, 24, 347-364.	16.8	277
51	The epigenetics of epithelial-mesenchymal plasticity in cancer. Nature Medicine, 2013, 19, 1438-1449.	30.7	1,030
52	An Integrin-Linked Machinery of Cytoskeletal Regulation that Enables Experimental Tumor Initiation and Metastatic Colonization. Cancer Cell, 2013, 24, 481-498.	16.8	174
53	Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity. Cell, 2013, 154, 61-74.	28.9	753
54	Poised with purpose: Cell plasticity enhances tumorigenicity. Cell Cycle, 2013, 12, 2713-2714.	2.6	30

#	Article	IF	Citations
55	Bengt Westermark and our current understanding of tumor pathogenesis. Upsala Journal of Medical Sciences, 2012, 117, 81-82.	0.9	1
56	Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State. Cell, 2012, 148, 1015-1028.	28.9	830
57	Cancer stem cells and epithelialâ€"mesenchymal transition: Concepts and molecular links. Seminars in Cancer Biology, 2012, 22, 396-403.	9.6	781
58	Cancer-Stimulated Mesenchymal Stem Cells Create a Carcinoma Stem Cell Niche via Prostaglandin E2 Signaling. Cancer Discovery, 2012, 2, 840-855.	9.4	299
59	The Outgrowth of Micrometastases Is Enabled by the Formation of Filopodium-like Protrusions. Cancer Discovery, 2012, 2, 706-721.	9.4	195
60	Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast. Cell, 2011, 145, 926-940.	28.9	788
61	Tumor Metastasis: Molecular Insights and Evolving Paradigms. Cell, 2011, 147, 275-292.	28.9	3,143
62	Hunting the elusive oncogene: a stroke of good luck. Nature Cell Biology, 2011, 13, 876-876.	10.3	2
63	A Perspective on Cancer Cell Metastasis. Science, 2011, 331, 1559-1564.	12.6	3,985
64	Metastatic colonization: Settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Seminars in Cancer Biology, 2011, 21, 99-106.	9.6	112
65	Hallmarks of Cancer: The Next Generation. Cell, 2011, 144, 646-674.	28.9	52,242
66	Phenotypic plasticity and epithelialâ€mesenchymal transitions in cancer and normal stem cells?. International Journal of Cancer, 2011, 129, 2310-2314.	5.1	191
67	Roles for microRNAs in the regulation of cell adhesion molecules. Journal of Cell Science, 2011, 124, 999-1006.	2.0	95
68	Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes and Development, 2011, 25, 646-659.	5.9	89
69	Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7950-7955.	7.1	1,024
70	miR-31: A crucial overseer of tumor metastasis and other emerging roles. Cell Cycle, 2010, 9, 2124-2129.	2.6	106
71	Autocrine TGF-Î² and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20009-20014.	7.1	682
72	Concurrent Suppression of Integrin Î±5, Radixin, and RhoA Phenocopies the Effects of miR-31 on Metastasis. Cancer Research, 2010, 70, 5147-5154.	0.9	104

#	Article	IF	Citations
73	Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15449-15454.	7.1	909
74	Metastasis suppression: a role of the Dice(r). Genome Biology, 2010, 11, 141.	9.6	7
75	MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis. Cell Cycle, 2009, 8, 3506-3512.	2.6	78
76	Integrin Î² ₁ -focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10290-10295.	7.1	329
77	Assaying microRNA loss-of-function phenotypes in mammalian cells: Emerging tools and their potential therapeutic utility. RNA Biology, 2009, 6, 541-545.	3.1	12
78	Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes and Development, 2009, 23, 2592-2597.	5.9	103
79	Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer, 2009, 9, 265-273.	28.4	2,951
80	Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening. Cell, 2009, 138, 645-659.	28.9	2,200
81	The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation, 2009, 119, 1420-1428.	8.2	8,252
82	The many faces of tumor dormancy. Apmis, 2008, 116, 548-551.	2.0	32
83	Ma et al. reply. Nature, 2008, 455, E9-E9.	27.8	1
84	Twisted epithelialâ€“mesenchymal transition blocks senescence. Nature Cell Biology, 2008, 10, 1021-1023.	10.3	79
85	Coevolution in the tumor microenvironment. Nature Genetics, 2008, 40, 494-495.	21.4	83
86	Leaving Home Early: Reexamination of the Canonical Models of Tumor Progression. Cancer Cell, 2008, 14, 283-284.	16.8	55
87	The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell, 2008, 133, 704-715.	28.9	7,695
88	Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin. Cell, 2008, 133, 994-1005.	28.9	395
89	Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis. Developmental Cell, 2008, 14, 818-829.	7.0	2,653
90	Mechanisms of malignant progression. Carcinogenesis, 2008, 29, 1092-1095.	2.8	152

#	Article	IF	Citations
91	Loss of E-Cadherin Promotes Metastasis via Multiple Downstream Transcriptional Pathways. Cancer Research, 2008, 68, 3645-3654.	0.9	1,298
92	The many faces of tumor dormancy. Apmis, 2008, 116, 548-551.	2.0	21
93	Heterogeneity of stromal fibroblasts in tumor. Cancer Biology and Therapy, 2007, 6, 618-619.	3.4	140
94	Is metastasis predetermined?. Molecular Oncology, 2007, 1, 263-264.	4.6	11
95	Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 2007, 449, 682-688.	27.8	2,382
96	Transformation of Different Human Breast Epithelial Cell Types Leads to Distinct Tumor Phenotypes. Cancer Cell, 2007, 12, 160-170.	16.8	281
97	A Lost Generation. Cell, 2006, 126, 9-10.	28.9	33
98	The Spemann organizer gene, <i>Goosecoid</i> , promotes tumor metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18969-18974.	7.1	201
99	The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nature Genetics, 2005, 37, 1047-1054.	21.4	404
100	Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion. Cell, 2005, 121, 335-348.	28.9	3,273
101	Inadvertent Cancer Research. Cancer Biology and Therapy, 2004, 3, 238-239.	3.4	5
102	Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis. Cell, 2004, 117, 927-939.	28.9	3,405
103	Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation. Molecular and Cellular Biology, 2002, 22, 2111-2123.	2.3	575
104	Metastasis genes: A progression puzzle. Nature, 2002, 418, 823-823.	27.8	733
105	Metastasis: objections to the same-gene model. Nature, 2002, 419, 560-560.	27.8	7
106	The Hallmarks of Cancer. Cell, 2000, 100, 57-70.	28.9	24,832
107	Inhibition of telomerase limits the growth of human cancer cells. Nature Medicine, 1999, 5, 1164-1170.	30.7	983
108	Creation of human tumour cells with defined genetic elements. Nature, 1999, 400, 464-468.	27.8	2,148

#	Article	IF	Citations
109	Bumps on the road to immortality. Nature, 1998, 396, 23-24.	27.8	30
110	Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene, 1998, 16, 1217-1222.	5.9	383
111	Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nature Genetics, 1998, 19, 182-186.	21.4	364
112	CELL CYCLE: The Expanding Role of Cell Cycle Regulators. Science, 1998, 280, 1035-1036.	12.6	108
113	Phenotype of mice lacking functional Deleted in colorectal cancer (Dec) gene. Nature, 1997, 386, 796-804.	27.8	717
114	A specific role for cyclin D1 in mammary gland development. Journal of Mammary Gland Biology and Neoplasia, 1997, 2, 335-342.	2.7	55
115	Cell-cycle control and its watchman. Nature, 1996, 381, 643-644.	27.8	278
116	Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature, 1996, 384, 470-474.	27.8	668
117	The Molecular Basis of Oncogenes and Tumor Suppressor Genes. Annals of the New York Academy of Sciences, 1995, 758, 331-338.	3.8	122
118	Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nature Genetics, 1994, 7, 353-361.	21.4	731
119	Oncogenes and tumor suppressor genes. Ca-A Cancer Journal for Clinicians, 1994, 44, 160-170.	329.8	119
120	Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature, 1993, 363, 45-51.	27.8	1,260
121	Association between GTPase activators for Rho and Ras families. Nature, 1992, 359, 153-154.	27.8	325
122	Effects of an Rb mutation in the mouse. Nature, 1992, 359, 295-300.	27.8	1,730
123	The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature, 1984, 312, 513-516.	27.8	1,107
124	Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature, 1984, 312, 649-651.	27.8	770
125	Characterization of a human colon/lung carcinoma oncogene. Nature, 1983, 302, 79-81.	27.8	211
126	Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature, 1983, 304, 596-602.	27.8	2,901

#	ARTICLE	IF	CITATIONS
127	Alteration of the genomes of tumor cells. Cancer, 1983, 51, 1971-1975.	4.1	27
128	Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell, 1982, 29, 161-169.	28.9	787
129	Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature, 1982, 297, 474-478.	27.8	894
130	Mechanism of activation of a human oncogene. Nature, 1982, 300, 143-149.	27.8	1,426
131	Unique transforming gene in carcinogen-transformed mouse cells. Nature, 1981, 289, 607-609.	27.8	96
132	Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature, 1981, 290, 261-264.	27.8	776
133	In vitro synthesis of infectious DNA of murine leukaemia virus. Nature, 1977, 269, 122-126.	27.8	100